Document is current
Any future updates will be listed below
-
Authors
Ansab, Muhammad
Razi, Sepideh
Nisa, Farwa
Araib, Eiman
Rath, Shree
Khan, Iqra
Ramzan, Noor Ul Huda
Dilawar, Esha
Saeed, Anwaar
- License Information
-
More Information
Article History
Received: 11 March 2025
Accepted: 10 June 2025
First Online: 1 July 2025
Declarations
:
: Not applicable.
: Not applicable.
: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Anwaar Saeed reports consulting or advisory board role with AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio therapeutics, Taiho, Amgen, Autem therapeutics, KAHR medical, Arcus therapeutics, Regeneron, Replimune and Daiichi Sankyo; institutional research funding from AstraZeneca, Bristol-Myers Squibb, Merck, Clovis, Exelixis, Actuate therapeutics, Incyte Corporation, Daiichi Sankyo, Five prime therapeutics, Amgen, Innovent biologics, Dragonfly therapeutics, Oxford Biotherapeutics, Replimune, Phanes therapeutics, Arcus therapeutics, Regeneron and KAHR medical.
